Hypoxia-Induced Endothelial NO Synthase Gene Transcriptional Activation Is Mediated Through the Tax-Responsive Element in Endothelial Cells
I n response to hypoxia, systemic arteries vasodilate, allowing more blood to be delivered to peripheral tissues. This vasodilation occurs within seconds after hypoxia and is maintained for several hours. 1 The molecular basis of hypoxic vasodilation is still somewhat unknown, although potassium channel activation, decreased ATP levels, increased intracellular acidification, decreased release of vasoconstrictors, such as endothelin and thromboxane, and increased release of vasodilators, such as adenosine, prostacyclin, and NO, have all been suggested as key components. 2, 3 NO plays an important role in vasodilation, and in endothelial cells, NO is catalyzed from the amino acid L-arginine and molecular oxygen by endothelial NO synthase (eNOS). The activity 4 and expression [5] [6] [7] [8] [9] [10] [11] of eNOS have been found to increase in response to hypoxia, but conflicting studies have observed a decrease 12, 13 or lack of response. 14 The discrepancies between these studies can potentially be explained by differences in either the duration of exposure to hypoxia or the endothelial cell type used.
Coulet et al 11 reported recently that 2 contiguous hypoxiaresponsive elements (HREs) located at Ϫ5375 to Ϫ5366 were identified in the eNOS gene promoter, and that transcription factor hypoxia-inducible factor (HIF)-2␣ preferentially bound to these elements under hypoxia, leading to the activation of eNOS gene transcription. However, several other studies using a construct of a shorter 5Ј-region flanking the eNOS gene (1600-bp), which is devoid of HRE, also clearly showed an increased transcriptional activity by hypoxia, 9, 11 implying that mechanism(s) other than the HIF/ HRE-mediated signaling pathway may be involved. To date, there has been only 1 study showing that enhanced eNOS gene transcription was mediated by redox-sensitive activating protein 1 signaling pathways. 9 In this study, we searched for other element(s) of the eNOS promoter that are responsible for hypoxia-induced transcriptional activation. We identified a Tax-responsive element (TRE) located from Ϫ924 to Ϫ921 within the eNOS promoter and showed that phosphorylated cAMP-responsive element (CRE) binding (CREB) protein (pCREB) preferentially binds to this response element under hypoxia and activates eNOS gene transcription.
Materials and Methods

Materials
H-89 was purchased from Calbiochem. Minimum essential medium, Hanks' balanced salt solution, newborn calf serum, penicillinstreptomycin, L-glutamine, trypsin-EDTA solution, and other plastic wares for cell culture were obtained from Gibco-BRL. Antibodies against eNOS and HIF-1␣ were purchased from Transduction Laboratories and BD Biosciences, respectively. Antibodies against pCREB (phosphorylated at Ser133) and CREB were purchased from Cell Signaling Technology, Inc.
Genomic DNA Extraction and Plasmid Construction
Genomic DNA was prepared from human blood leukocytes. Human blood leukocytes were obtained from Ansan Health Study, 15 and all of the procedures for human research were approved by the Institutional Review Board of Ansan Health Study. Using genomic DNA as a template, a DNA fragment of the 5Ј-flanking region of the eNOS gene (Ϫ1600 to ϩ22 nucleotides) was amplified by PCR and designated eNOS(Ϫ1600). The sense and antisense primers containing KpnI and XhoI sites, respectively, for PCR amplification are shown as follows: sense, 5Ј-TTGACCCTGAGGATGCCAGT-3Ј; antisense, 5Ј-TGCTGCCTGCTCGAGCAGAGC-3Ј. Furthermore, 5Ј-deletion DNA fragments of the eNOS promoter at Ϫ1400, Ϫ962, Ϫ873, and Ϫ428 were also amplified by PCR and designated eNOS(Ϫ1400), eNOS(Ϫ962), eNOS(Ϫ873), and eNOS(Ϫ428), respectively. Each sense primer is shown as follows: eNOS(Ϫ1400), sense 5Ј-ACTGGGAAGGCGAGGTGGTG-3Ј; eNOS(Ϫ962), sense 5Ј-AGTCTCTGAGGTACCGAAATC-3Ј; eNOS(Ϫ873), sense 5Ј-GAGTGCTGGGGTACCCCACAA-3Ј; and eNOS(Ϫ428), sense 5Ј-ATCCCCTGCTACAGAAACAA-3Ј. The same antisense sequences were used to construct all of the 5Ј-deletion DNA fragments. In a separate experiment, site-directed mutagenesis (A3 G at Ϫ922) of eNOS(Ϫ962) was also carried out using a modified sense primer 5Ј-TCCGGTACCTCAGATGGCACAGAA-3Ј and designated meNOS(Ϫ962). The synthesized PCR products containing each of the 6 DNA fragment sequences were digested and fused into luciferase reporter gene plasmids, which were designated pGL2-eNOS(Ϫ1600), pGL2-eNOS(Ϫ1400), pGL2-eNOS(Ϫ962), pGL2-eNOS(Ϫ873), pGL2-eNOS(Ϫ428), and pGL2-m-eNOS(Ϫ962), respectively (Figures 3B, 4B, and 4E).
Cell Culture, Transfections, and Hypoxia Treatment
Bovine aortic endothelial cells (BAECs) were isolated and cultured as described. 16 BAECs were transfected with (3 g each) pGL2-eNOS(Ϫ1600), pGL2-eNOS(Ϫ1400), pGL2-eNOS(Ϫ962), pGL2-eNOS(Ϫ873), pGL2-eNOS(Ϫ428), and pGL2-m-eNOS(Ϫ962) using Lipofectin (Invitrogen Inc) according to the manufacturer's instructions. In a separate experiment, BAECs were also transfected with 3 g of dominant-negative inhibitor of CREB, termed A-CREB. 17 BAECs or transfectants were then subjected to either hypoxia or normoxia for the indicated times, respectively. Protocols for cell culture, transfections, luciferase assays, and hypoxia treatments are described in detail in the online data supplement (available online at http://www.hypertensionaha.org).
Measurement of NO Release
Measurement of NO release is described in detail in the online data supplement.
Electrophoretic Mobility Shift Assay
The method for electrophoretic mobility shift assay (EMSA) is described in detail in the online data supplement. The sequences of the sense strands of double-stranded oligonucleotides used as probes and competitors in the EMSA were as follows, with the consensus motifs of CRE and TRE3 italicized: The CRE probe (sense strand) used was 5Ј-CGGGAAGCGTGCGTCACTGAATGACA-3Ј ( Figure  3C ). At this moment, it should be noted that the CRE sequence indicated in the eNOS gene is not a "classical" palindromic DNA sequence (TGACGTCA) of CRE, but it has been widely used as a putative CRE sequence in the previous studies. 18, 19 In a separate experiment, a positive control for CRE probe with a classical palindromic DNA sequence of CRE (italicized) used was 5Ј-AGAGATTGCCTGACGTCAGAGAGCTAG-3. 20 The wild-type TRE3 probe used was 5Ј-CCAGCCCCTCAGATGACACAGAAC-TACAAAC-3Ј ( Figure 4C ), and mutant TRE3 (mTRE3, with mutation sequence in boldface) was 5Ј-CCAGCCCCTCAGATGGCA-CAGAACTACAAAC-3Ј ( Figure 4C ). For the mutation of TRE3 sequence, the site-specific mutation (A3 G) at Ϫ922 of the eNOS promoter was directed from the discovery of eNOS gene single-nucleotide polymorphic sites. 21, 22 
Western Blot Analysis
Western blot analysis is described in detail in the online data supplement.
Real-Time RT-PCR
Measurement of the levels of eNOS mRNA is described in detail in the online data supplement.
Statistical Analysis
All of the data are presented as mean (SD) with n indicating the number of experiments. Statistical significance was determined by the Student t test for 2 points. Differences were deemed statistically significant at P values Ͻ0.05.
Results
Hypoxia Increases eNOS Protein Level and NO Production
Hypoxia (1% O 2 concentration), as evidenced by the increase in HIF-1␣ expression ( Figure 1A ), increased the NO produc- Figure 1 . Hypoxia increases eNOS expression and NO production by BAECs. Confluent monolayers of BAECs were treated with 1% O 2 for the indicated times. Cell lysates were prepared, and protein was detected by Western blot analysis using antibody specific for HIF-1␣ (␣) or eNOS (B). NO released by BAECs was measured by the Griess method with a minor modification (B). Each bar represents mean NO production (after normalization to total cellular protein) relative to controlϮSD. Statistically significant at *PϽ0.05 and **PϽ0.01 (nϭ4 to 5).
tion by BAECs in a time-dependent manner ( Figure 1B) . The maximal increase in NO levels (2.78Ϯ0.14-fold of the control) was observed after 24-hour treatment, and this increase subsequently fell over the next 48-hour period. Therefore, unless otherwise stated, all of the subsequent experiments were performed using this condition (1% O 2 concentration for 24-hour treatment). Western blot analysis revealed that this increase was accompanied by an increase in eNOS protein expression ( Figure 1B ).
Increase in eNOS Protein Level and NO Production by Hypoxia Is Mediated Through pCREB-Mediated Pathway
Hypoxia is reported to increase the phosphorylation of CREB. 23 This result, considered in context with a previous finding that beraprost sodium (BPS), an orally active prostacyclin analogue, increased eNOS gene transcription by pCREB-mediated pathways, 18 prompted us to test whether these hypoxia-stimulated increases in eNOS expression and NO production are also mediated by pCREB-CRE signaling pathways. As shown in Figure 2A , hypoxia increased the phosphorylation of CREB with no alteration of CREB expression. The maximal increase in CREB phosphorylation was observed after 24-hour treatment, showing a similar time-dependent pattern to that of eNOS expression. To determine whether the increase in CREB phosphorylation mediates hypoxia-induced increases in eNOS protein level and NO production, we first used H-89, a specific protein kinase A (PKA) inhibitor. PKA is well known to phosphorylate CREB in a variety of cells. 24, 25 As shown in Figure 2B , pretreatment with H-89 (10 mol/L for 1-hour treatment) significantly decreased CREB phosphorylation by hypoxia. This drug, however, did not alter CREB expression. Furthermore, H-89 significantly attenuated hypoxia-induced increases in eNOS expression and NO production. To further clarify a role of pCREB in this mechanism, we next transfected A-CREB, a dominant-negative inhibitor of CREB, into BAECs. A-CREB, devoid of Ser133 phosphorylation site, is well known to inhibit CRE-mediated transcription by DNA binding of pCREB 17 to the specific promoter sequence of several target genes. Recently, A-CREB was also reported to inhibit the phosphorylation of CREB, leading to a decrease in CRE-mediated steroidogenic acute regulatory protein gene transcription induced by insulin-like growth factor 1. 26 Parallel to the results with H-89, we found that transfection of A-CREB also decreased CREB phosphorylation by hypoxia ( Figure 2C ). Furthermore, this transfection significantly decreased hypoxia-stimulated eNOS expression and NO production by hypoxia. Taken together, our data suggest that the stimulatory effect of hypoxia on eNOS expression and NO production in BAECs is mediated at least in part by CREB phosphorylation. Hypoxia increases phosphorylation of CREB by PKA-dependent signaling pathway. BAECs were prepared and treated with hypoxia as described in Figure 1 . The amount of pCREB was measured by Western blot analysis with antibody specific for CREB phosphorylated at Ser133 and normalized to total CREB level (A). In some experiments, BAECs were pretreated with 10 mol/L H-89 for 1 hour (B), or transfected with a dominant-negative inhibitor of CREB, A-CREB (C), and the pCREB and NO were measured (B and C). The control cells were treated with vehicle 0.01% dimethyl sulfoxide (DMSO) (B) or empty pcDNA3.1 (Mock) vector (C) only. Data are presented as described in Figure 1 (nϭ4 to 6) .
CRE Within ؊1.6-kb eNOS Gene Promoter Is Not Involved in Transcriptional Activation of eNOS Gene by Hypoxia
To test whether hypoxia increased the eNOS expression via the interaction between pCREB and CRE within the eNOS promoter, we first examined the transcriptional activation of eNOS by hypoxia. In agreement with previous reports, 8, 9, 18, 27 we clearly found that hypoxia (for 24-hour treatment) increased the amount of eNOS mRNA ( Figure 3A) , suggesting that the stimulatory effect of hypoxia on eNOS gene expression occurs at least at the level of transcription. We next constructed pGL2-eNOS(Ϫ1600), as described in the Methods section, to explore the role of the interaction between pCREB and CRE in the transcriptional activation of the eNOS gene. As shown in Figure 3B , hypoxia clearly increased the promoter activity (2.36Ϯ0.18-fold of the control) in cells transfected with pGL2-eNOS(Ϫ1600). Based on a Genomatix database search (http://genomatix.de), we identified 1 putative CRE site located from Ϫ733 to Ϫ727 of the eNOS promoter ( Figure 3B ). However, using pGL2-eNOS(Ϫ873) containing this putative CRE site, no increase in promoter activity was observed in response to hypoxia, suggesting that this CRE site is not involved in hypoxiastimulated eNOS transcription. To further corroborate this finding, we explored EMSA to find whether the pCREB induced by hypoxia bound to the CRE. As shown in Figure   Figure 3 . CRE site is not involved in hypoxia-stimulated eNOS gene transcription. The relative eNOS mRNA expression levels obtained by real-time RT-PCR analysis were calculated as the ratio of eNOS expression in hypoxia-treated cells to those in normoxic cells, and both were normalized to GAPDH mRNA level. Results are meanϮSD. Statistically significant at **PϽ0.01 (nϭ3; A). Left, eNOS promoter-luciferase deletion constructs. BAECs were transfected with each construct, and were exposed to normoxia or hypoxia for 24 hours. Right, relative activity of each of the constructs in the BAECs. Luciferase activity was measured by the Luciferase Assay System, normalized to total the cellular protein, and expressed relative to that of pGL2-eNOS(Ϫ1600) without hypoxia treatment. Results are meanϮSD and are statistically significant at **PϽ0.01 (nϭ4; B). Sense sequence of the double-stranded probe for the CRE site in the eNOS gene promoter region used in the EMSA is shown; consensus motif of CRE is italicized (C). Nuclear extracts from the normoxic and hypoxic BAEC were incubated with radiolabeled probe containing the CRE sequence and subjected to EMSA and supershift assay using anti-pCREB antibody (Ab). Normal protein-DNA complexes and pCREB or CREB-DNA complexes are indicated by an arrow (D).
3D, the supershift experiment using anti-pCREB antibody revealed that pCREB did not bind to the CRE site. This result is valid, because we found that pCREB clearly bound to the positive control. We also found that this binding was specific, because it was inhibited in a dose-dependent manner by a 10-and 50-molar excess of unlabeled CRE (from positive control or from eNOS gene) oligonucleotides. These data suggest that pCREB may not bind to the CRE in the eNOS promoter. A positive control contains a "classical" palindromic DNA sequence (TGACGTCA) of CRE, whereas CRE in the eNOS gene is very similar in sequence to the classical CRE with only 1 nucleotide (A) deleted (TGCGTCA).
TRE Site Located From ؊924 to ؊921 of the eNOS Promoter Is Identified as a pCREB Binding Sequence Responsible for Hypoxia-Stimulated eNOS Gene Transcription
To map the region(s) of the eNOS promoter responsible for hypoxia-stimulated eNOS transcription, we further searched a Genomatix database. In addition to CRE, we found that there are 4 more putative sequences, so-called TREs, for CREB binding ( Figure 4A ). Progressive 5Ј-deletion from Ϫ1600 to Ϫ962 [pGL2-eNOS(Ϫ1400) and pGL2-eNOS(Ϫ962)] did not significantly alter the increased eNOS promoter activity by hypoxia ( Figure 4B ). However, further deletion from Ϫ962 to Ϫ873 [pGL2-eNOS(Ϫ873)] completely attenuated the increased promoter activity, whereas deleting down to Ϫ428 [pGL2-eNOS(Ϫ428)] did not reduce activity further ( Figures 3B and 4B) . This result suggests an important role for the TRE3 site in hypoxia-stimulated eNOS gene transcription. To further corroborate these findings, nuclear extracts after hypoxia were incubated with wild-type (TRE3) and mutant double-stranded oligonucleotides (mTRE3) corresponding with the TRE3 region and analyzed by EMSA ( Figure 4C ). The sequence of mTRE3 was adopted from the well-known single-nucleotide polymorphic sequence identified by several genomic epidemiology studies. 20, 21 As shown in Figure 4D , incubation with TRE3 resulted in significantly retarded complexes (left); more prominent retarded complex was found when incubated with extracts from hypoxic cells. The supershift experiment using anti-pCREB antibody demonstrated that pCREB bound to the TRE3 probe. The binding of pCREB to the TRE3 was specific, because this binding was significantly inhibited in a dose-dependent manner by a 10-and 50-molar excess of unlabeled wild-type TRE3 oligonucleotides. In contrast, competition and supershift assays showed that pCREB did not bind to the mTRE3 probe (right), although incubation with mTRE3 resulted in a more prominent retarded complex compared with incubation with TRE3. These results defined the hypoxia-responsive sequence as TRE3 located at Ϫ924 to Ϫ921 of the eNOS promoter. The importance of TRE3 for the observed effects was further supported by a finding that the construct pGL2-meNOS(Ϫ962), which contains mTRE3 in the context of pGL2-eNOS(Ϫ962), was unresponsive to hypoxia ( Figure  4E ). Furthermore, cotransfection of A-CREB significantly inhibited the luciferase activity of pGL2-eNOS(Ϫ962) induced by hypoxia, whereas no alteration in luciferase activity of pGL2-m-eNOS(Ϫ962) was observed, suggesting that pCREB bound to the TRE3 sequence, leading to an increase in eNOS gene transcription.
Discussion
Our study demonstrates that hypoxia increases NO production by activating pCREB-mediated eNOS gene transcription. Promoter analysis of the eNOS gene mapped the hypoxiaresponsive sequence to TRE, located at Ϫ924 to Ϫ921. These data are further confirmed by EMSA, supershift assay, and site-specific mutation analysis. We believe that this is the first solid evidence that eNOS gene expression is induced in response to hypoxia through the interaction between pCREB and TRE.
Our current finding, that hypoxia increases pCREBmediated eNOS gene transcription, deserves particular attention, because cAMP-mediated vasodilation has been generally considered to be eNOS independent. 28 -30 However, it has been reported recently that cAMP increased NO production via either phosphorylation of eNOS 30, 31 or expression of eNOS, 18 suggesting a direct effect of cAMP on eNOS modulation. A particularly interesting finding from a previous study, which relates to our current study, was that BPS, an orally active prostacyclin analogue, increased the promoter activity of the eNOS gene through the interaction between pCREB and CREs. 18 In this previous study, PKA was found to phosphorylate CREB, and PKA inhibitors completely blocked the effect of BPS on eNOS gene transcription and NO production. This PKA-mediated, pCREB-stimulated eNOS gene transcription was fairly reproduced by our current data using H-89 treatment and A-CREB transfection ( Figure  2B and 2C ). However, it should be noted that the phosphorylation of CREB was first detected at 6 hours after hypoxia, peaked at 24 hours, and gradually declined thereafter ( Figure  2A ), whereas BPS increased pCREB at a much earlier time point (30 minutes) and peaked at 1 hour. 18 Furthermore, the authors of the previous report defined 2 contiguous CRE sequences at Ϫ733 and Ϫ603 as a pCREB binding site. Interestingly, however, this result was not reproduced by our current study, because we did not observe any of the interactions of pCREB with CREs that they had defined ( Figure 3D ). Instead, we found that pCREB induced by hypoxia treatment bound to the TRE site. At present, the reason for these incompatible results is not fully understood, although it may be attributable to different experimental conditions: hypoxia treatment versus BPS treatment.
Although the involvement of TRE, the human T-cell leukemia virus type 1 (HTLV-1), a CRE-like site, in the regulation of hypoxia-stimulated eNOS gene transcription is of great interest, a detailed underlying mechanism is not clearly understood at the present time. It was reported previously that Tax, a unique oncoprotein encoded by a viral genome, interacts with HTLV-1 long terminal repeat indirectly via binding to CREB, which binds to TRE. 32, 33 Furthermore, Tax was known to stabilize CREB/DNA complexes and to enhance the binding affinity of CREB to TRE sites. 32, 34 Biochemical experiments have demonstrated that, in the presence of Tax, CREB binds to the TRE in a phosphorylation-independent manner, 35,36 thereby serving as a cofactor for Tax activation of HTLV-1 transcription. However, in the The TRE site located from Ϫ924 to Ϫ921 of the eNOS promoter is identified as a pCREB binding sequence responsible for hypoxia-stimulated eNOS transcription. Based on a Genomatix database search, 5 putative sequences for CREB binding (4 TREs and 1 CRE) within the human eNOS promoter are found; consensus motifs of CRE and TREs are italicized (A). Relative luciferase activity of each of the constructs in the BAECs after transfection was determined, and data are presented as described in Figure 3 (nϭ3; B) . Sense sequences of the double-stranded probes for TRE3 and mTRE3 sites in the eNOS gene promoter region used in the EMSA are shown. The mutation site (A3 G at Ϫ922) in bold is directed by a well-known SNP site identified by several genomic epidemiology studies (C). EMSA and supershift assay were done with TRE3 or mTRE3 probes as described in Figure 3 (D) . The relative luciferase activities of pGL2-eNOS(Ϫ962) and pGL2-m-eNOS(Ϫ962) in the BAECs after transfection with or without A-CREB were determined, and data are presented as described in Figure 3 (nϭ3; E) . absence of Tax, as shown in uninfected mammalian cells, CREB binds to the CRE sites only after its phosphorylation via the cAMP-dependent PKA signaling pathway. In this regard, it was expected that pCREB should bind to the CRE within the eNOS promoter. Unexpectedly, however, our data showed that pCREB induced by hypoxia bound to the TRE but not CRE (Figures 3D and 4D) . These data strongly suggest that Tax may not be involved in our current system. Although CREB was reported to bind equally to the TRE at normoxia and hypoxia in virus-infected cells, 37 to our knowledge, our study is the first to show that pCREB binds to the TRE in uninfected mammalian cells. Nonetheless, it is worthwhile to test whether there are other unknown Tax-like protein(s) in relation to TRE-mediated eNOS gene regulation in BAECs; such a test, however, is beyond the scope of our study.
The finding in our study of a specific TRE site responsible for hypoxia-stimulated eNOS gene transcription had not been observed by 2 recent reports. At present, the reasons for these incompatible results have yet to be clarified. Authors of 2 previous reports stated in their reports that they constructed and used an eNOS promoter sequence that was obtained either from GeneBank Accession No. AC092466 11 or from 2 previously published reports. 19, 38 Interestingly, however, it was found that the eNOS promoter sequence presented from GeneBank or previously published reports was a mutant eNOS gene sequence containing a well-known single nucleotide polymorphism (SNP) site (A3 G mutation at Ϫ922). In this regard, it should be noted that this SNP loses the TRE consensus motif. We further tested our result by EMSA and found that pCREB did not bind to the mutant TRE3 site ( Figure 4D ), suggesting that the consensus motif (TGAC) of the TRE3 region in the eNOS gene promoter might play an important role in interacting with pCREB. From this result, our data demonstrate, for the first time, that an A3 G SNP site at Ϫ922 of the eNOS gene may be another important functional locus for regulating eNOS gene expression, in addition to a T3 C mutation at Ϫ786. Several studies have found previously that the repressed transcription of the eNOS gene is linked to a T3 C SNP at Ϫ786, which results in an increased risk of cardiovascular disease. Thus, a T3 C mutation at Ϫ786 has already been recognized as the most important functional locus for eNOS gene regulation, 15, 21, 22 although this SNP was reported to be in linkage disequilibrium with 2 other SNPs (A3 G SNP at Ϫ922 and T3 A SNP at Ϫ1468). 15, 21 Further study will be needed to clarify this issue.
Perspectives
Our results shed light on the molecular mechanisms underlying hypoxia-stimulated eNOS gene transcription, which implicates pCREB-TRE mediation. This study extends our understanding of the mechanisms involved in NO regulation by other cardiovascular risk factor(s). It was reported previously that cigarette smoking, known as an important risk factor in cardiovascular disease, decreased eNOS gene expression in endothelial cells and decreased the amount of lung cAMP, 39 an upstream molecule of PKA/pCREB-mediated signaling pathway. The identification of TRE site in the eNOS gene, thus, may hold a promise in unraveling cigarette smoking-induced vascular dysfunction. Finally, our results underscore the potential of the TRE site as a novel therapeutic target for the design of drugs aimed at improving endothelial function in NO dysregulation-related cardiovascular disease, such as hypertension.
Methods
Cell Culture, Transfections, and Hypoxia Treatment
Bovine aortic endothelial cells (BAEC) were isolated exactly as previously For transfection, BAEC were transferred to 6-well plates and allowed to grow until they were approximately 60% confluent, at which time they were transfected with pGL2-eNOS(-1600), pGL2-eNOS(-1400), pGL2-eNOS(-962), pGL2-eNOS(-873), pGL2-eNOS(-428), and pGL2-m-eNOS(-962) (3 µg each) using Lipofectin (Invitrogen Inc., Carlsbad, CA) according to the manufacturer's instructions. In a separate experiment, BAEC were also transfected with 3 µg dominant-negative inhibitor of CREB, termed A-CREB, 2 using Lipofectin. In all transfection experiments, BAEC were cotransfected with 3 µg α-actin-driven β-galactosidase expression plasmid for normalization of transfection efficiency. After transfection, the transfectants were further grown for 24 hours, washed three times with magnesium-and calcium-free phosphate-buffered saline (PBS), and lysed directly on each plate by the addition of 100 µL of 1 × reporter lysis buffer (Promega Co., Madison, WI). After complete lysis, the lysates were centrifuged at 14,000 × g for 1 min, and 10 µL of supernatant were subjected to the luciferase assay. Luciferase activity of the transfectants was measured using a Luciferase Assay System (Promega) as previously described, 3 and α-actindriven β-galactosidase activity was measured using a β-Galactosidase Enzyme Assay System (Promega). All data were normalized as relative light units/β-galactosidase activity.
For hypoxia treatment, BAEC cultured at 80% confluency were subjected to either hypoxia or normoxia for indicated times, respectively. The hypoxia was achieved as previously described 4 using a hypoxia chamber (COY Laboratory Products, Inc., Hypoxic Glove Box, MI), which maintained a humidified atmosphere with a low oxygen tension (5% CO 2 − 1% O 2 ).
Measurement of NO Release
NO production by BAEC was measured as the nitrite (a stable metabolite of NO) concentration in cell culture supernatants, as described in previous studies, by the cells during the 1 hour incubation in the Kreb's solution following hypoxiccondition treatment of a specified duration. Therefore, subsequent NO production was solely dependent on eNOS activity at the end of these treatments.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts from BAEC with or without hypoxia treatment were isolated by the method of Lee et al. 6 The sequences of the sense strands of double-stranded oligonucleotides used as probes and competitors in the EMSA were as follows, with the consensus motifs of CRE and TRE3 underlined, and mutation of wild-type TRE3 sequence in boldface: The CRE probe (sense strand, with consensus motif underlined) used was 5'-CGGGAAGCGTGCGTCACTGAATGACA-3' (Figure 3C ). At this moment, it should be noted that the CRE sequence indicated in the eNOS gene is not a "classical" palindromic DNA sequence (TGACGTCA) of CRE but it has been widely used as a putative CRE sequence in the previous studies. 7, 8 In a separate experiment, a positive control for CRE probe with a classical palindromic DNA sequence of CRE (underlined) used was 5'-AGAGATTGCCTGACGTCAGAGAGCTAG-3. 9 The wildtype TRE3 probe used was 5'-CCAGCCCCTCAGATGACACAGAACTACAAAC-3'
( Figure 4C ) and mutant TRE3 (mTRE3, with mutation sequence in boldface) was 5'-CCAGCCCCTCAGATGGCACAGAACTACAAAC-3' (Figure 4C ). For the mutation of TRE3 sequence, the site-specific mutation (A →G) at −922 of the eNOS promoter was directed from the discovery of eNOS gene single nucleotide polymorphic sites. and pCREB (1:1000), followed by the corresponding secondary antibody, and finally developed using enhanced chemiluminescence reagents (ECL, Amersham, DE). The level of actin expression was used as an internal control.
Real-Time Reverse Transcription-PCR
The levels of eNOS mRNA were quantified by real-time reverse transcription (RT)-PCR using a SYBR ® Green PCR Master Mix (ABI 7700, Applied Biosystems, CA) as previously described 12 , with minor modifications. In brief, the total RNA from BAEC cultured under hypoxia or normoxia for 24 hours was extracted using TRIzol reagent (Gibco-BRL) according to the manufacturer's instructions. Reverse transcription was first performed to synthesize cDNA using total RNA (0.5 µg), oligo- 
